iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $15.86 Consensus Price Target from Analysts

Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) have earned an average recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $15.86.

ITOS has been the subject of several research reports. JPMorgan Chase & Co. lowered iTeos Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $15.00 to $8.00 in a research report on Tuesday, May 13th. Wells Fargo & Company restated an “equal weight” rating and issued a $12.00 target price (down previously from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Leerink Partnrs cut iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 14th. Piper Sandler restated an “overweight” rating and issued a $12.00 target price (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Leerink Partners reiterated a “market perform” rating and set a $9.00 price target (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th.

iTeos Therapeutics Stock Up 0.1%

ITOS opened at $10.17 on Thursday. iTeos Therapeutics has a 52-week low of $4.80 and a 52-week high of $18.13. The company has a 50 day moving average of $8.98 and a two-hundred day moving average of $7.73. The company has a market cap of $389.21 million, a P/E ratio of -3.35 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.14. Research analysts anticipate that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm’s stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider owned 2,108,594 shares of the company’s stock, valued at $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director David Hallal sold 38,228 shares of the firm’s stock in a transaction on Friday, June 6th. The stock was sold at an average price of $10.24, for a total value of $391,454.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,939,307 shares of company stock valued at $16,202,116. Insiders own 12.50% of the company’s stock.

Institutional Trading of iTeos Therapeutics

A number of institutional investors have recently bought and sold shares of ITOS. Y Intercept Hong Kong Ltd bought a new position in iTeos Therapeutics during the fourth quarter valued at about $142,000. US Bancorp DE increased its position in iTeos Therapeutics by 40.1% in the 4th quarter. US Bancorp DE now owns 16,919 shares of the company’s stock worth $130,000 after buying an additional 4,843 shares during the period. Victory Capital Management Inc. increased its position in shares of iTeos Therapeutics by 6.8% during the fourth quarter. Victory Capital Management Inc. now owns 101,759 shares of the company’s stock valued at $782,000 after purchasing an additional 6,519 shares during the period. Raymond James Financial Inc. bought a new stake in shares of iTeos Therapeutics during the fourth quarter valued at approximately $1,159,000. Finally, AlphaQuest LLC increased its position in shares of iTeos Therapeutics by 274.9% during the fourth quarter. AlphaQuest LLC now owns 41,318 shares of the company’s stock valued at $317,000 after purchasing an additional 30,298 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.